Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery by Østergaard, Lauge et al.
 
  
 
Aalborg Universitet
Differences in mortality in patients undergoing surgery for infective endocarditis
according to age and valvular surgery
Østergaard, Lauge; Smerup, Morten Holdgaard; Iversen, Kasper; Jensen, Andreas
Dalsgaard; Dahl, Anders; Chamat-Hedemand, Sandra; Bruun, Niels Eske; Butt, Jawad
Haider; Bundgaard, Henning; Torp-Pedersen, Christian; Køber, Lars; Fosbøl, Emil
Published in:
BMC Infectious Diseases
DOI (link to publication from Publisher):
10.1186/s12879-020-05422-8
Creative Commons License
CC BY 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Østergaard, L., Smerup, M. H., Iversen, K., Jensen, A. D., Dahl, A., Chamat-Hedemand, S., Bruun, N. E., Butt,
J. H., Bundgaard, H., Torp-Pedersen, C., Køber, L., & Fosbøl, E. (2020). Differences in mortality in patients
undergoing surgery for infective endocarditis according to age and valvular surgery. BMC Infectious Diseases,
20(1), [705]. https://doi.org/10.1186/s12879-020-05422-8
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
RESEARCH ARTICLE Open Access
Differences in mortality in patients
undergoing surgery for infective
endocarditis according to age and valvular
surgery
Lauge Østergaard1* , Morten Holdgaard Smerup1, Kasper Iversen2, Andreas Dalsgaard Jensen1, Anders Dahl2,
Sandra Chamat-Hedemand2, Niels Eske Bruun3,4,5, Jawad Haider Butt1, Henning Bundgaard1,
Christian Torp-Pedersen6,7, Lars Køber1 and Emil Fosbøl1
Abstract
Background: Infective endocarditis (IE) is associated with high mortality. Surgery may improve survival and reduce
complications, but the balance between benefit and harm is difficult and may be closely related to age and type of
surgical intervention. We aimed to examine how age and type of left-sided surgical intervention modified mortality
in patients undergoing surgery for IE.
Methods: By crosslinking nationwide Danish registries we identified patients with first-time IE undergoing surgical
treatment 2000–2017. Patients were grouped by age < 60 years, 60–75 years, and ≥ 75 years. Multivariable adjusted
Cox proportional hazard analysis was used to examine factors associated with 90-day mortality.
Results: We included 1767 patients with IE undergoing surgery, 735 patients < 60 years (24.1% female), 766 patients
60–75 years (25.8% female), and 266 patients ≥75 years (36.1% female). The proportions of patients undergoing
surgery were 35.3, 26.9, and 9.1% for patients < 60 years, 60–75 years, and > 75 years, respectively. Mortality at 90
days were 7.5, 13.9, and 22.3% (p < 0.001) for three age groups. In adjusted analyses, patients 60–75 years and
patients ≥75 years were associated with a higher mortality, HR = 1.84 (95% CI: 1.48–2.29) and HR = 2.47 (95% CI:
1.88–3.24) as compared with patients < 60 years. Factors associated with 90-day mortality were: mitral valve surgery,
a combination of mitral and aortic valve surgery as compared with isolated aortic valve surgery, age, diabetes, and
prosthetic heart valve implantation prior to IE admission.
Conclusions: In patients undergoing surgery for IE, mortality increased significantly with age and 1 in 5 died above
age 75 years. Mitral valve surgery as well as multiple valve interventions augmented mortality further.
Keywords: Infective endocarditis, Cardiac surgery, Endocarditis
Background
Infective endocarditis (IE) remains a disease with an in-
hospital mortality around 20% [1–3] and several studies
have suggested that the incidence of IE is increasing -
especially among patients aged > 75 years [2, 4–7]. It has
been reported that surgery is performed in 23–52% of
patients with IE from population-based cohorts [5, 8–
10], however surgery in elderly patients may be challen-
ging due to the burden of comorbidities and high peri-
operative risk. Several studies have described temporal
changes of the epidemiologic characteristics of patients
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with IE and patients with IE now constitute an older
population with a higher degree of comorbidities than
previously [3, 5, 11, 12]. Little epidemiologic data exist
on the prognosis following heart valve surgery for IE by
age groups [3, 5, 11–15].
In a meta-analysis, including 16 studies examining risk
scores for the assessment of in-hospital mortality in pa-
tients undergoing surgical treatment for IE, age, among
other factors, was found to be associated with an in-
creased risk of in-hospital mortality [16]. Further, age is
included as a predictor in several surgical risk scores
used for IE [17–20] but little data are present on the
prognosis for IE patients > 75 years of age. Surgery on
the mitral valve versus the aortic valve necessitates more
extensive cardiac surgery, however differences in mortal-
ity between aortic and mitral valve surgery are sparsely
described in patients with IE. The aim of this study was
to examine mortality in patients undergoing surgical
treatment for IE by age groups and to investigate differ-
ences by type of left-sided surgical valve intervention.
Further, we aimed to examine factors associated with
90-day mortality.
Methods
Data sources
In Denmark, every citizen is provided with a personal
identifier making it possible to link nationwide health
registries [21]. For this study we used the Danish Na-
tional Patient Registry, the Danish Population Registry,
and the Prescription Registry. In brief, the Danish Na-
tional Patient Registry holds information on every
hospitalization since 1977 based on the discharge sum-
mary and diagnosis codes provided solely by the treating
physician. One primary diagnosis is given (mandatory),
while several secondary diagnoses may be given. The
International Classification of Diseases (ICD-10) has
been used since 1994. From 1996 and onwards surgical
procedures were added to the registry using the Nordic
Medico-Statistical Committee classification of surgical
procedures. The registry has been described in detail
previously [22]. The Danish Population Registry holds
information on date of birth, date of death, and sex. The
Danish Prescription Registry holds information on every
prescription filled by a Danish pharmacy from 1994. The
registry has been described in detail previously [23]. In-
formation on medication given in-hospital is not avail-
able from the registries used.
Study population, follow-up and outcome
Patients with first-time IE undergoing cardiac surgery
from 2000 to 2017 were included. The study population
was grouped in 1) patients < 60 years of age at IE admis-
sion, 2) patients aged 60–75 years, and 3) patients aged
≥75 years. In a supplementary analysis, the population
undergoing left-sided valvular intervention was grouped
in 1) isolated aortic valve surgery, 2) isolated mitral valve
surgery, and 3) a combination of aortic and mitral valve
surgery. Further, in supplementary material, analysis of
cardiac valve intervention was stratified by age groups
(1: < 60 years, 2: 60–75 years, 3: ≥75 years).
IE was defined from the following ICD-10 codes: I33,
I38, and I398. Patients were required to have a hospital
stay of minimum 14 days unless they died during the
first 14 days of admission [24]. We accounted for trans-
fers between hospitals and departments using a 24 h cri-
teria for discharge/admission overlap. The positive
predictive value of the ICD-10 codes for IE in the Da-
nish National Patient Registry using the abovementioned
criteria is 90% [25]. Heart valve surgery was defined
from the Danish National Patient Registry using the pro-
cedure codes defined in Supplementary Table 1. Subclas-
sification of the surgical valve procedure was conducted
as follows: mechanical aortic valve replacement, biopros-
thetic aortic valve replacement, other aortic valve re-
placement (xenograft, homograft, and aortic valve
replacements classified as “other”), surgical aortic valve
intervention without valve replacement, mechanical mi-
tral valve replacement, bioprosthetic mitral valve re-
placement, and surgical mitral valve intervention
without valve replacement.
Patients were followed from the date of heart valve
surgery until death, December 2017, or a maximum of 5
years of follow-up, whichever came first. The primary
outcome was all-cause mortality 90 days after valve sur-
gery. Further, we report in-hospital and five-years
mortality.
Covariates
Medical history was assessed as a diagnosis of myocar-
dial infarction, heart failure, atrial fibrillation/flutter, mi-
tral or aortic valve disease, cardiac implantable
electronic device, prosthetic heart valve prior to IE,
renal disease, dialysis, peripheral vascular disease,
cerebrovascular disease, cancer, chronic obstructive
pulmonary disorder, and liver disease at any time
prior to IE admission from the Danish National Pa-
tient Registry. Renal disease included patients with
prior nephritic and nephrotic syndrome, patients
with renal failure, anuria or oliguria, hypertensive
renal disease with and without heart failure. Cancer
was defined as a malignant neoplasm from any
organ. Age and sex were assessed from the Danish
Population Registry and concomitant pharmacother-
apy was assessed from the Danish Prescription Regis-
try as a filled prescription in a period of 6 months
prior to IE admission. Diabetes was defined from the
prescription of glucose lowering medication as done
previously [26].
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Statistics
Baseline characteristics of the study population were
presented in counts and percentages for categorical vari-
ables and with the median and 25 and 75 percentiles for
continuous variables. Comparison of baseline character-
istics between groups (1: < 60 years, 2: 60–75 years, 3:
≥75 years) were conducted using the chi-square test for
categorical variables and the Kruskal-Wallis test for con-
tinuous variables. In-hospital mortality was assessed as
the number of patients surgically treated who died dur-
ing IE admission divided by the total number of patients
surgically treated for IE by age groups. The chi-square
test was used for investigating statistically significant dif-
ference between groups of in-hospital mortality. Mortal-
ity at 90 days and 5 years for the three age groups were
plotted using Kaplan-Meier estimates. Associated risk of
in-hospital mortality between age groups and by type of
valve intervention was assessed in a multivariable ad-
justed logistic regression and 90 days mortality was
assessed using Cox proportional hazard analysis. The
following covariates were included in the models: type of
surgical intervention during IE admission (mitral vs aor-
tic vs mitral and aortic valve surgery), sex, heart failure,
atrial fibrillation, age group, acquired mitral valve disease
before IE admission, acquired aortic valve disease before
IE admission, inserted cardiac implantable electronic de-
vice, prosthetic heart valve prior to IE admission, dialysis
prior to IE admission, chronic obstructive pulmonary
disease, diabetes, and calendar year periods. The as-
sumption of proportional hazard was examined and for
the investigation of 5 years mortality in patients under-
going left-sided valvular intervention the proportional
hazard assumption was violated. A landmark analysis
was conducted splitting the follow-up time at 90 days of
follow-up. Calendar year was at first hand included as a
continuous variable; however the assumption of linearity
was not met, and the variable was categorized accord-
ingly. Linearity of age was confirmed and to illustrate
the associated risk of mortality with increasing age, a re-
stricted cubic spline was modeled from the Cox regres-
sion model. The median age was used as reference value.
We identified factors at baseline associated with 90
days mortality using Cox proportional hazard analysis.
Results are presented with a hazard ratio. The level of
statistical significance was p < 0.05. Data management
and statistical analysis was conducted using SAS soft-
ware 9.4 (SAS Institute, Inc., Cary, NC, USA) and the
statistical software R version 3.5.0 [27].
Results
Description of the study population
We identified a total of 7845 patients admitted for first-
time IE in the period from 2000 to 2017, of which 1767
patients (22.5%) underwent cardiac surgery during IE
admission; 735 (41.6%), 766 (43.4%), and 266 (15.1%) pa-
tients were < 60 years of age, 60–75 years, and ≥ 75 years,
respectively. The proportion of patients with IE under-
going surgery was 35.3, 26.9, and 9.1% for the three age
groups, respectively. The age group ≥75 years undergo-
ing surgical intervention had a higher burden of comor-
bidities compared with the two younger study groups,
Table 1. Of the total study population (1767 patients),
isolated aortic valve surgery was conducted in 917 pa-
tients (51.9%), isolated mitral valve surgery in 498 pa-
tients (28.2%), and a combination of mitral and aortic
valve surgery in 255 patients (14.4%), right-sided valve
surgery in 42 patients (2.4%), and a combination of left-
and right-sided surgery in 55 patients (3.1%). For pa-
tients undergoing left-sided surgical intervention (n =
1670), baseline characteristics are shown in Supplemen-
tary Table 2 and overall, it was seen that patients under-
going mitral valve surgery more often were female.
Mortality according to age groups
The in-hospital mortality was overall 11.6% and for
age groups it was 6.4%, 13.6%, and 20.3% for patients
< 60 years, 60–75 years, and ≥ 75 years of age, respectively
(p < 0.001), Supplementary Table 3. In adjusted analysis,
the associated odds of in-hospital mortality were higher
among patients 60–75 years and ≥ 75 years, OR = 2.00
(95% CI: 1.36–2.94) and OR = 3.33 (95% CI: 2.10–5.28),
respectively as compared with patients < 60 years. The
mortality at 90 days of follow-up was 7.5%, 13.9%, and
22.3% for patients < 60 years, 60–75 years, and ≥ 75 years
of age (p < 0.001), respectively while the 5 years mortality
was 19.7%, 37.0%, and 46.2% (p < 0.001), respectively, Fig. 1
and Supplementary Table 3. In adjusted analyses, patients
60–75 years and patients ≥75 years were associated with a
higher mortality, HR = 1.84 (95% CI: 1.48–2.29) and HR =
2.47 (95% CI: 1.88–3.24), respectively as compared with
patients < 60 years.
Mortality according to type of left-sided valvular surgery
For patients undergoing isolated aortic valve surgery,
isolated mitral valve surgery, a combination of aortic
and mitral valve surgery, the in-hospital mortality was
8.1%, 14.3%, and 18.0% (p < 0.001), respectively, Supple-
mentary Table 3. In an adjusted analysis, the associated
odds of in-hospital mortality were higher among patients
undergoing isolated mitral valve surgery OR = 2.15 (95%
CI: 1.42–3.26), a combination of aortic and mitral valve
surgery OR = 2.99 (95% CI: 1.94–4.62) as compared with
patients undergoing isolated aortic valve surgery. The
90 days mortality for these groups were 8.9%, 16.7%, and
16.5% (p < 0.001), while the 5 years mortality was 28.9%,
32.7%, and 31.6% (p = 0.07), respectively, Fig. 2 and Sup-
plementary Table 3. In an adjusted analysis, we found
differences in the associated risk of mortality by type of
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valve intervention with 0–90 days of follow-up, HR =
2.04 (95% CI: 1.43–2.92) and HR = 2.12 (95% CI: 1.43–
3.12) for patients undergoing isolated mitral valve sur-
gery, a combination of aortic and mitral valve surgery,
respectively as compared with patients undergoing iso-
lated aortic valve surgery. In a landmark analysis, with
90-days to 5 years of follow-up, the associated risk of
mortality was: HR = 1.00 (95% CI: 0.72–1.38) and HR =
0.90 (95% CI: 0.61–1.34), respectively as compared with
patients undergoing isolated aortic valve surgery.
Mortality according to type of valvular surgery by age
groups
Mortality of isolated aortic valve surgery, isolated
mitral valve surgery and a combination of aortic and
mitral valve intervention for the three age groups
are presented in the Supplementary material. The
overall results presented in the Supplementary ma-
terial showed that for isolated aortic valve surgery,
the 90 days mortality were 5.4%, 9.8%, and 15.6% for
patients < 60 years, 60–75 years and ≥ 75 years, re-
spectively, Supplementary Table 3. For isolated mi-
tral valve surgery, the 90 days mortality were 10.8%
for < 60 years, 18.5% for 60–75 years, and 29.6% ≥75
years. For a combination of aortic and mitral valve
surgery the 90 days mortality were 9.0% for < 60
years, 16.0% for 60–75 years, and 36.3% for ≥75
years, Supplementary Table 3. Results of multivari-
able adjusted analyses are shown in Supplementary
material, Supplementary Figures 2, 3, 4 and confirm
unadjusted results showing an increased associated
mortality with increasing age.
Table 1 Baseline characteristics for patients undergoing valve surgery for IE by age groups
All < 60 years 60–75 years ≥75 years
Number 1767 735 766 266
Age, median (IQR) 63 [52.7, 71.6] 50 [41.4, 55.6] 67.7 [63.8, 71.3] 78.2 [76.3, 80.3] < 0.001
Female, N (%) 471 (26.7) 177 (24.1) 198 (25.8) 96 (36.1) 0.0006
Medical history prior to IE admission, N (%)
AMI 102 (5.8) 26 (3.5) 52 (6.8) 24 (9.0) 0.001
Heart failure 220 (12.5) 56 (7.6) 116 (15.1) 48 (18.0) < 0.001
Afib 241 (13.6) 35 (4.8) 142 (18.5) 64 (24.1) < 0.001
Mitral valve disease 165 (9.3) 52 (7.1) 86 (11.2) 27 (10.2) 0.02
Aortic valve disease 455 (25.7) 107 (14.6) 227 (29.6) 121 (45.5) < 0.001
CIED 71 (4.0) 16 (2.2) 34 (4.4) 21 (7.9) < 0.001
Prosthetic heart valve 228 (12.9) 51 (6.9) 104 (13.6) 73 (27.4) < 0.001
Renal disease 123 (7.0) 57 (7.8) 53 (6.9) 13 (4.9) 0.29
Dialysis 28 (1.6) 12 (1.6) 14 (1.8) < 4 0.48
Peripheral vascular disease 149 (8.4) 34 (4.6) 78 (10.2) 37 (13.9) < 0.001
Cerebrovascular disease 158 (8.9) 38 (5.2) 80 (10.4) 40 (15.0) < 0.001
Cancer 191 (10.8) 44 (6.0) 104 (13.6) 43 (16.2) < 0.001
COPD 128 (7.2) 21 (2.9) 77 (10.1) 30 (11.3) < 0.001
Liver disease 57 (3.2) 28 (3.8) 24 (3.1) 5 (1.9) 0.31
Diabetes 182 (10.3) 49 (6.7) 95 (13.1) 34 (12.8) < 0.001
Medication six months prior to IE admission, N (%)
Diuretics 543 (30.7) 120 (16.3) 301 (39.3) 122 (45.9) < 0.001
Beta blockade 409 (23.1) 100 (13.6) 223 (29.1) 86 (32.3) < 0.001
RAS inhibition 547 (31.0) 133 (18.1) 305 (39.8) 109 (41.0) < 0.001
Lipid lowering medication 428 (24.2) 82 (11.2) 243 (31.7) 103 (38.7) < 0.001
Corticosteroids 138 (7.8) 42 (5.7) 69 (9.5) 26 (9.8) 0.02
Aspirin 367 (20.8) 70 (9.5) 175 (24.1) 104 (39.1) < 0.001
Anticoagulants 298 (16.9) 74 (10.1) 147 (20.2) 61 (22.9) < 0.001
Antibiotics 899 (50.9) 359 (48.8) 374 (51.4) 149 (56.0) 0.13
IE infective endocarditis, IQR interquartile range, 25th and 75th percentile, AMI acute myocardial infarction, Afib atril fibrillation/flutter, CIED cardiac implantable
electronic device, COPD chronic obstructive pulmonary disease, RAS renin-angiotensin system
The percentages of the qualitative variables are shown in parentheses
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Factors associated with 90-day mortality
We found that isolated mitral valve surgery, and a com-
bination of aortic and mitral valve surgery were factors
associated with an increased risk of 90-day mortality
as compared with patients undergoing isolated aortic
valve surgery, Fig. 3. Further, increasing age, prosthetic
heart valve implantation prior to IE admission, and dia-
betes were factors associated with an increased risk of
90-day mortality, Fig. 3. Including age as a continuous
variable in the multivariable model was associated with
an increased risk of mortality (per 1 year increase), HR =
1.04 (95% CI: 1.02–1.05). In Supplementary Figure 1, the
associated risk of mortality is plotted according to in-
creasing age.
Discussion
This study investigated the associated in-hospital, 90-
day, and 5 years mortality in patients undergoing
Fig. 1 Mortality by age groups. The figure shows the 90-day mortality (left panel) and 5 year mortality (right panel) by age groups
Fig. 2 Mortality by type of left-sided valve surgery. The figure shows the 90-day mortality (left panel) and 5 year mortality (right panel) by type of
left-sided valve intervention
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valvular surgery for IE by age groups and type of left-
sided valvular intervention. Our study had four major
findings. First, the proportions of patients undergoing
surgery were 35.3%, 26.9%, and 9.1% for patients < 60 years,
60–75 years, and > 75 years, respectively. Second, the
90-day mortality was around 1/15 patients, 1/7 patients,
and 1/5 patients for < 60 years, 60–75 years, and ≥ 75 years
of age, respectively. Third, in adjusted analyses, the
mortality at 90 days was higher in patients undergoing
mitral valve surgery, and a combination of mitral and
aortic valve surgery as compared to isolated aortic
valve surgery. Further, increasing age, prosthetic heart
valve implantation prior to IE admission, and diabetes
were factors associated with an increased 90-day mortality.
Fourth, for patients ≥75 years undergoing a combination
of aortic and mitral valve surgery, 36% died within 90 days
of surgery.
Proportion of patients with IE undergoing surgery
Our study, based on nationwide data, showed that 22.5%
of patients with IE underwent cardiac valve surgery dur-
ing IE admission. In comparison, a study from the Inter-
national Collaboration on Endocarditis (ICE) identified
that 57% of patients with left-sided IE underwent surgery
[28]. Patients included in the ICE cohort were highly se-
lected from tertiary centers and it has previously been
shown that these patients more often undergo surgical
intervention [29, 30]. Data from a large prospective co-
hort from 156 centers, 40 countries included 3116 cases
of IE and found that 51.2% underwent cardiac surgery.
Around 8.0% of the included cases were recruited from
low-volume centers [8]. Further, from a French
population-based study it was identified that 49% of 390
patients with IE underwent early valve surgery [11]. Our
findings are based on data from an unselected patient
cohort and provide novel results on a patient population
sparsely described. A study from 14 French hospitals in-
cluded 120 patients with IE ≥75 years and identified that
15.8% underwent valvular surgery [31]. A Spanish study
from four tertiary centers identified that 17.6% (N = 6) of
octogenarian patients underwent surgery.
Mortality by age groups
Characteristics of patients with IE have changed over the
last decades and patients with IE are older at the time of
diagnosis, the majority is male, and more patients have a
Fig. 3 Associated risk of 90-day mortality after valve surgery for IE. The figure shows the associated risk of 90-day mortality. *Prosthetic heart valve
prior to IE admission compared with patients with native valves. Afib: atrial fibrillation/flutter, CIED: cardiac implantable electronic device, COPD:
chronic obstructive pulmonary disease
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prosthetic heart valve [12, 32]. The decision of surgical
intervention may be difficult in elderly patients and our
results shed light on the prognosis subsequent to valve
surgery in patients with IE. Our study showed that pa-
tients ≥75 years who underwent surgery, the in-hospital
and 90-day mortality was tripled compared with patients
< 60 years. Several risk-scores have been developed to
predict in-hospital mortality in patients with IE with an
indication for surgery and age constitutes an important
parameter in these risk scores [17–20, 33]. However, no
data from nationwide registries have explored the actual
in-hospital, intermediate, and long-term mortality in pa-
tients undergoing surgery for IE across age groups. A
prospective cohort of patients with IE from Spain,
mainly from tertiary centers, identified 3120 patients
with IE from 2008 to 2015. In patients ≥80 years the in-
hospital mortality was 34.7% and age ≥ 80 years were as-
sociated with an increased mortality. From our data, an
in-hospital mortality of 20.3% was identified among pa-
tients ≥75 years [34]. A single-center study from
Australia, investigated 465 patients undergoing cardiac
surgery for IE and found, among other factors, that in-
creasing age, active bacterial endocarditis, and a high
European System for Cardiac Operative Risk Evaluation
score were associated with an increased risk of in-
hospital mortality [35]. A previously mentioned Spanish
study with data from tertiary centers concluded that age
was not an independent predictor of in-hospital mortal-
ity [36]. This study population may be biased by selec-
tion since only patients from tertiary centers were
included [36].
Mortality by type of valvular intervention
Our findings showed that mitral valve surgery, and a
combination of mitral and aortic valve surgery were not
only associated with significantly higher in-hospital and
90-day mortality in general but also across age groups.
Careful considerations of surgical indication in patients
undergoing mitral valve surgery are necessary. In a land-
mark analysis, we identified that the increased associated
risk of mortality for patients undergoing mitral valve
surgery as compared with isolated aortic valve surgery
was found during the initial 90 days of follow-up after
valvular surgery. After the initial 90 days of follow-up,
no differences in the associated risk of mortality was
identified between by type of valvular surgery.
The authors studying the ICE cohort found that an in-
crement in the Society of Thoracic Surgeons (STS) score
of mortality risk was associated with an increased six-
month mortality, however type of valvular surgical inter-
vention was not assessed [28]. Our findings suggest that
valve location is critical to assess the in-hospital and 90-
day mortality of patients with IE. Mitral valve surgery is
a major cardiac surgical intervention as compared with
isolated aortic valve surgery and previous studies have
found a higher mortality in patients undergoing mitral
valve surgery as compared with aortic valve surgery [37,
38]. A study from the STS Adult Cardiac Surgery Data-
base, identified that among 13,617 surgical procedures
for IE, 40.2% was conducted on the mitral valve, 35.7%
on the aortic valve, and 19.9% was conducted on more
than one valve [33]. For the assessment of morbidity and
mortality, the authors identified, among other factors,
that age > 60 years and that surgery on more than one
valve were factors associated with major morbidity and
postoperative mortality [33]. Our study is in line with
these findings and supplements current knowledge with
unique data on mortality by age groups and type of valve
intervention [33]. Several single-center studies from
Sweden, Spain, Switzerland, and the United States, have
identified an in-hospital mortality between 9 and 26%
and a 5 years mortality between 22.4 and 25.0% in pa-
tients undergoing surgery for IE [39–42]. Further, a
single-center study from Canada investigated patients
with IE undergoing a combination of aortic and mitral
valve surgery, including 90 patients with an all-cause
mortality at 5 years of follow-up at 32% [43]. From na-
tionwide data, we identified an all-cause mortality of
31.6% with up to 5 years of follow-up in patients under-
going a combination of aortic and mitral valve surgery.
We found that 9.1% of all patients with IE ≥75 years
underwent surgery and among the surgically treated pa-
tients undergoing a combination of aortic and mitral
valve surgery more than one third died within 90 days of
surgery (Supplementary material).
Strengths and limitations
The main strength of this study is that data were pro-
vided from reliable nationwide registries ensuring an un-
selected, large cohort of patients undergoing surgery for
IE with long-term follow-up. However, some limitations
were present. First, we had no data from echocardiog-
raphy which could have helped characterize the infec-
tious spread on cardiac structures. Second, data on the
indication of surgery and microbiological etiology was
not accessible from the registries used. Third, risk fac-
tors for 90-day mortality were assessed in multivariable
adjusted analyses, however residual confounding may
exist, which may have influenced the estimates
presented.
Conclusion
In patients undergoing surgery for IE, we identified a 90-
day mortality at 1/15 patients, 1/7 patients, and 1/5 pa-
tients for < 60 years, 60–75 years, and ≥ 75 years of age,
respectively. Mitral valve surgery and combined mitral
and aortic valve surgery were associated with an in-
creased risk of 90-day mortality. Age, prosthetic heart
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valve implantation prior to IE admission, and diabetes
were factors associated with an increased risk of 90-day
mortality. For patients ≥75 years undergoing a combin-
ation of aortic and mitral valve surgery around 36% died
within 90 days of surgery.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05422-8.
Additional file 1: Supplementary Figure 1. Associated risk of 90-day
and 5 years mortality by increasing age. The figure shows the multivari-
able adjusted associated risk of 90-day and 5 years mortality by age. Ref-
erence value is the median age.
Additional file 2: Supplementary Figure 2. Mortality by age groups
for isolated aortic valve surgery. The figure shows the 90-day mortality
(left panel) and 5 year mortality (right panel) by age groups for surgical
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